I learned myriad life and professional lessons from my travels.
Tildrakizumab-asmn (Ilumya) approved for the treatment of moderate-to-severe plaque psoriasis.
The addition of atezolizumab (Tecentriq) to chemotherapy may improve outcomes for patients with advanced non-small cell lung cancer.
A PET scan could quickly indicate whether EGRF-targeted therapy would be beneficial to patients with non-small cell lung cancer.
Adding tenofovir disoproxil fumarate to prevention regimens may not effectively stop hepatitis B virus transmission to infants.
Standard colorectal cancer screening guidelines may not accurately assess risks in certain patients.
Top news of the day from across the health care landscape.

Most Popular

Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.